JP2023543826A5 - - Google Patents
Info
- Publication number
- JP2023543826A5 JP2023543826A5 JP2023519496A JP2023519496A JP2023543826A5 JP 2023543826 A5 JP2023543826 A5 JP 2023543826A5 JP 2023519496 A JP2023519496 A JP 2023519496A JP 2023519496 A JP2023519496 A JP 2023519496A JP 2023543826 A5 JP2023543826 A5 JP 2023543826A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011054187 | 2020-09-29 | ||
| CN202011054187.5 | 2020-09-29 | ||
| PCT/CN2021/121285 WO2022068809A1 (zh) | 2020-09-29 | 2021-09-28 | 抗cd3抗体以及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543826A JP2023543826A (ja) | 2023-10-18 |
| JP2023543826A5 true JP2023543826A5 (https=) | 2024-10-07 |
Family
ID=80949658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519496A Pending JP2023543826A (ja) | 2020-09-29 | 2021-09-28 | 抗ｃｄ３抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230374132A1 (https=) |
| EP (1) | EP4223777A4 (https=) |
| JP (1) | JP2023543826A (https=) |
| KR (1) | KR20230079409A (https=) |
| CN (2) | CN116261590B (https=) |
| AU (1) | AU2021353368B2 (https=) |
| CA (1) | CA3196933A1 (https=) |
| TW (2) | TW202547880A (https=) |
| WO (1) | WO2022068809A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117897404A (zh) * | 2021-08-02 | 2024-04-16 | 信达生物制药(苏州)有限公司 | 抗CD79b×CD3双特异性抗体及其用途 |
| JP2025524024A (ja) | 2022-07-22 | 2025-07-25 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 多重特異性抗体の重鎖及び軽鎖の相同対合を促進する変異体 |
| CN115792242A (zh) * | 2022-11-23 | 2023-03-14 | 苏州逻晟生物医药有限公司 | 一种测定抗cd70单克隆抗体直接激活cd70下游通路能力的方法 |
| TW202502826A (zh) | 2023-06-06 | 2025-01-16 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｇｐｒｃ５ｄ／ｂｃｍａ／ｃｄ３三特異性抗體的製備及其用途 |
| WO2025131075A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3和抗cd3多特异性抗体及用途 |
| WO2025247325A1 (en) * | 2024-05-30 | 2025-12-04 | Hanx Biopharmaceuticals, (Wuhan) Ltd. | Antibody-drug conjugates targeting trbv12 and uses thereof |
| WO2026006494A1 (en) * | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-cd3 antibodies and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| KR102211837B1 (ko) * | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| KR101973060B1 (ko) * | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| CA3101271A1 (en) * | 2018-05-24 | 2019-11-28 | Janssen Biotech, Inc. | Anti-cd3 antibodies and uses thereof |
| CN111518214B (zh) * | 2019-02-03 | 2023-09-22 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的双特异性抗体及其制备方法和应用 |
| JP7410143B2 (ja) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
| WO2020168554A1 (zh) * | 2019-02-22 | 2020-08-27 | 武汉友芝友生物制药有限公司 | 改造的Fc片段，包含其的抗体及其应用 |
| CN111662382A (zh) * | 2019-03-06 | 2020-09-15 | 瑞阳(苏州)生物科技有限公司 | 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用 |
| TWI841790B (zh) * | 2019-09-30 | 2024-05-11 | 大陸商和鉑醫藥（上海）有限責任公司 | 靶向cd3的抗體、雙特異性抗體及其用途 |
| US20250074996A1 (en) * | 2021-02-19 | 2025-03-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF |
-
2021
- 2021-09-28 JP JP2023519496A patent/JP2023543826A/ja active Pending
- 2021-09-28 CN CN202180066476.3A patent/CN116261590B/zh active Active
- 2021-09-28 EP EP21874469.6A patent/EP4223777A4/en active Pending
- 2021-09-28 TW TW114131058A patent/TW202547880A/zh unknown
- 2021-09-28 WO PCT/CN2021/121285 patent/WO2022068809A1/zh not_active Ceased
- 2021-09-28 TW TW110136040A patent/TWI898054B/zh active
- 2021-09-28 AU AU2021353368A patent/AU2021353368B2/en active Active
- 2021-09-28 CA CA3196933A patent/CA3196933A1/en active Pending
- 2021-09-28 CN CN202511420584.2A patent/CN121108344A/zh active Pending
- 2021-09-28 KR KR1020237014541A patent/KR20230079409A/ko active Pending
- 2021-09-28 US US18/246,930 patent/US20230374132A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023543826A5 (https=) | ||
| JP2021516973A5 (https=) | ||
| JP2021516975A5 (https=) | ||
| JP2021516974A5 (https=) | ||
| JP2021533726A5 (https=) | ||
| JP2021515568A5 (https=) | ||
| JP2021515566A5 (https=) | ||
| JP2021515565A5 (https=) | ||
| JP2021516976A5 (https=) | ||
| JP2020522280A5 (https=) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2020522281A5 (https=) | ||
| KR20200020902A (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2022533538A5 (https=) | ||
| JP2024016024A5 (https=) | ||
| JP2024540148A5 (https=) | ||
| IL276675B2 (en) | Anti-PD-1 antibodies and uses thereof | |
| JP2021525806A5 (https=) | ||
| JP2023517754A5 (https=) | ||
| JP2024500512A5 (https=) | ||
| JP2024522075A5 (https=) | ||
| JP2024519078A5 (https=) | ||
| JP2024536358A5 (https=) | ||
| JP2024502670A5 (https=) |